Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

Effects of rasagiline on olfactory function in patients with Parkinson's disease

(2013) Antje Haehner et al.   MOVEMENT DISORDERS

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

(2013) C. Warren Olanow et al.   MOVEMENT DISORDERS

Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials

(2013) Lawrence W. Elmer   PARKINSONISM & RELATED DISORDERS

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease

(2013) Géraldine H. Petit et al.   PLoS One

Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease

(2012) Santiago Perez-Lloret et al.   CLINICAL NEUROPHARMACOLOGY

Hyposmia in Parkinson's disease

(2012) Maria Victoria Alvarez et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Determination of minimal clinically important change in early and advanced Parkinson's disease

(2011) Robert A. Hauser et al.   MOVEMENT DISORDERS

The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale

(2010) Lisa M. Shulman et al.   ARCHIVES OF NEUROLOGY

The D3dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5

(2009) Pei-Chun Chen et al.   JOURNAL OF NEUROCHEMISTRY

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

(2009) Angelo Antonini et al.   LANCET NEUROLOGY